🇺🇸 FDA
Pipeline program

RP-L401

RP-L401-0120

Phase 1 mab terminated

Quick answer

RP-L401 for Infantile Malignant Osteopetrosis is a Phase 1 program (mab) at ROCKET PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ROCKET PHARMACEUTICALS, INC.
Indication
Infantile Malignant Osteopetrosis
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials